Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Статины и печень: взгляд кардиолога
Статины и печень: взгляд кардиолога
Остроумова О.Д. Статины и печень: взгляд кардиолога. Consilium Medicum. 2017; 19 (10): 85–88. DOI: 10.26442/2075-1753_19.10.85-88
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Статья посвящена безопасности статинов с точки зрения гепатотоксичности. Представлены данные рекомендаций в плане мониторирования функции печени у пациентов, получающих статины. Обсуждаются вопросы выбора оптимальной схемы лечения статинами с позиции соотношения эффективность/безопасность.
Ключевые слова: статины, ингибиторы редуктазы гидроксиметил-глютарового кофермента А, розувастатин, эффективность, безопасность,
побочные эффекты, гепатотоксичность, фармакокинетика.
Key words: statin, HMGCoA reductase inhibitor, rosuvastatin, efficacy, safety, adverse effects, hepatotoxicity, pharmacokinetics.
Ключевые слова: статины, ингибиторы редуктазы гидроксиметил-глютарового кофермента А, розувастатин, эффективность, безопасность,
побочные эффекты, гепатотоксичность, фармакокинетика.
________________________________________________
Key words: statin, HMGCoA reductase inhibitor, rosuvastatin, efficacy, safety, adverse effects, hepatotoxicity, pharmacokinetics.
Полный текст
Список литературы
1. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37 (39): 2999–3058.
2. Catapano AL, Graham I, De Backer G et al. Рекомендации ЕОК/ЕОА по диагностике и лечению дислипидемий 2016. Рабочая группа Европейского общества кардиологов (ЕОК) и Европейского общества атеросклероза (ЕОА) по диагностике и лечению дислипидемий. При участии: Европейской ассоциации профилактики сердечно-сосудистых заболеваний и реабилитации (EACPR). Рос. кардиологич. журн. 2017; 5 (145): 7–77. / Catapano AL, Graham I, De Backer G et al. Rekomendatsii EOK/EOA po diagnostike i lecheniiu dislipidemii 2016. Rabochaia gruppa Evropeiskogo obshchestva kardiologov (EOK) i Evropeiskogo obshchestva ateroskleroza (EOA) po diagnostike i lecheniiu dislipidemii. Pri uchastii: Evropeiskoi assotsiatsii profilaktiki serdechno-sosudistykh zabolevanii i reabilitatsii (EACPR). Ros. kardiologich. zhurn. 2017; 5 (145): 7–77. [in Russian]
3. Кукес В.Г. и др. Клиническая фармакология. Учебник. Под ред. В.Г.Кукеса, Д.А.Сычева. М.: ГЭОТАР-Медиа, 2015. / Kukes V.G. i dr. Klinicheskaia farmakologiia. Uchebnik. Pod red. V.G.Kukesa, D.A.Sycheva. M.: GEOTAR-Media, 2015. [in Russian]
4. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97 (8A): 52C–60C.
5. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013; 6: 390–9.
6. Силивончик Н.Н. Статины и печень: безопасность. Мед. новости. 2011; 8: 24–30. / Silivonchik N.N. Statiny i pechen': bezopasnost'. Med. novosti. 2011; 8: 24–30. [in Russian]
7. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28 (1): 26–35.
8. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012; 10: 264–71.
9. Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287–92.
10. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62–5.
11. Dongiovanni P, Petta S, Mannisto V et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705–12.
12. Кухарчук В.В. Гиполипидемические препараты. Глава 17 в справочнике по медикаментозному лечению сердечно-сосудистых заболеваний. Под ред. Е.И.Чазова. М.: Практика, 2015; с. 261–2. / Kukharchuk V.V. Gipolipidemicheskie preparaty. Glava 17 v spravochnike po medikamentoznomu lecheniiu serdechno-sosudistykh zabolevanii. Pod red. E.I.Chazova. M.: Praktika, 2015; s. 261–2. [in Russian]
13. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9: 698–705.
14. Lioudaki E, Ganotakis ES, Mikhailidis DP. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011; 17: 3632–43.
15. Korantzopoulos P, Tzimas P, Kalantzi K et al. Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res 2009; 40: 582–9.
16. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009; 205: 533–7.
17. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8 (Suppl. 1): S40–3.
18. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5 (2): 177–93.
19. McKenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19 (8): 689–98.
20. Wlodarczyk J, Sullivan D, Smith M. Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials. Am J Cardiol 2008; 102: 1654–62.
21. Everett BM, Mora S, Glynn RJ et al. Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER). Am J Cardiol 2014; 114: 1682–9.
22. Fellström BC, Jardine AG, Schmieder RE et al for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395–407.
23. Kjekshus J, Apetrei E, Barrios V et al for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–61.
24. Tavazzi L, Tognoni G, Franzosi M et al on behalf of the GISSI-HF investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004; 6: 635–41.
25. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231–9.
26. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223–30.
27. Brewer HB. Benefit-Risk Assessment of Rosuvastatin 10 to 40 Milligrams. Am J Cardiol 2003; 92 (Suppl.): 23K–29K.
28. Bays H, Cohen DE, Chalasani N, Harrison SA. An Assessment by the Statin Liver Safety Task Force: 2014 Update. J Clin Lipidology 2014; 8: S47–S57.
29. Antonopoulos S, Mikros S, Mylonopoulou M et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233–4.
30. Nakahara T, Hyogo H, Kimura Y et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res 2012; 42: 1065–72.
31. Напалков Д.А. Безопасность статинов: что нужно знать практикующему врачу? Рациональная фармакотерапия в кардиологии. 2014; 10 (3): 331–5. / Napalkov D.A. Bezopasnost' statinov: chto nuzhno znat' praktikuiushchemu vrachu? Ratsional'naia farmakoterapiia v kardiologii. 2014; 10 (3): 331–5. [in Russian]
2. Catapano AL, Graham I, De Backer G et al. Rekomendatsii EOK/EOA po diagnostike i lecheniiu dislipidemii 2016. Rabochaia gruppa Evropeiskogo obshchestva kardiologov (EOK) i Evropeiskogo obshchestva ateroskleroza (EOA) po diagnostike i lecheniiu dislipidemii. Pri uchastii: Evropeiskoi assotsiatsii profilaktiki serdechno-sosudistykh zabolevanii i reabilitatsii (EACPR). Ros. kardiologich. zhurn. 2017; 5 (145): 7–77. [in Russian]
3. Kukes V.G. i dr. Klinicheskaia farmakologiia. Uchebnik. Pod red. V.G.Kukesa, D.A.Sycheva. M.: GEOTAR-Media, 2015. [in Russian]
4. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97 (8A): 52C–60C.
5. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013; 6: 390–9.
6. Silivonchik N.N. Statiny i pechen': bezopasnost'. Med. novosti. 2011; 8: 24–30. [in Russian]
7. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28 (1): 26–35.
8. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012; 10: 264–71.
9. Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287–92.
10. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62–5.
11. Dongiovanni P, Petta S, Mannisto V et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705–12.
12. Kukharchuk V.V. Gipolipidemicheskie preparaty. Glava 17 v spravochnike po medikamentoznomu lecheniiu serdechno-sosudistykh zabolevanii. Pod red. E.I.Chazova. M.: Praktika, 2015; s. 261–2. [in Russian]
13. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9: 698–705.
14. Lioudaki E, Ganotakis ES, Mikhailidis DP. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011; 17: 3632–43.
15. Korantzopoulos P, Tzimas P, Kalantzi K et al. Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res 2009; 40: 582–9.
16. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009; 205: 533–7.
17. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8 (Suppl. 1): S40–3.
18. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5 (2): 177–93.
19. McKenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19 (8): 689–98.
20. Wlodarczyk J, Sullivan D, Smith M. Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials. Am J Cardiol 2008; 102: 1654–62.
21. Everett BM, Mora S, Glynn RJ et al. Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER). Am J Cardiol 2014; 114: 1682–9.
22. Fellström BC, Jardine AG, Schmieder RE et al for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395–407.
23. Kjekshus J, Apetrei E, Barrios V et al for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–61.
24. Tavazzi L, Tognoni G, Franzosi M et al on behalf of the GISSI-HF investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004; 6: 635–41.
25. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231–9.
26. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223–30.
27. Brewer HB. Benefit-Risk Assessment of Rosuvastatin 10 to 40 Milligrams. Am J Cardiol 2003; 92 (Suppl.): 23K–29K.
28. Bays H, Cohen DE, Chalasani N, Harrison SA. An Assessment by the Statin Liver Safety Task Force: 2014 Update. J Clin Lipidology 2014; 8: S47–S57.
29. Antonopoulos S, Mikros S, Mylonopoulou M et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233–4.
30. Nakahara T, Hyogo H, Kimura Y et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res 2012; 42: 1065–72.
31. Napalkov D.A. Bezopasnost' statinov: chto nuzhno znat' praktikuiushchemu vrachu? Ratsional'naia farmakoterapiia v kardiologii. 2014; 10 (3): 331–5. [in Russian]
2. Catapano AL, Graham I, De Backer G et al. Рекомендации ЕОК/ЕОА по диагностике и лечению дислипидемий 2016. Рабочая группа Европейского общества кардиологов (ЕОК) и Европейского общества атеросклероза (ЕОА) по диагностике и лечению дислипидемий. При участии: Европейской ассоциации профилактики сердечно-сосудистых заболеваний и реабилитации (EACPR). Рос. кардиологич. журн. 2017; 5 (145): 7–77. / Catapano AL, Graham I, De Backer G et al. Rekomendatsii EOK/EOA po diagnostike i lecheniiu dislipidemii 2016. Rabochaia gruppa Evropeiskogo obshchestva kardiologov (EOK) i Evropeiskogo obshchestva ateroskleroza (EOA) po diagnostike i lecheniiu dislipidemii. Pri uchastii: Evropeiskoi assotsiatsii profilaktiki serdechno-sosudistykh zabolevanii i reabilitatsii (EACPR). Ros. kardiologich. zhurn. 2017; 5 (145): 7–77. [in Russian]
3. Кукес В.Г. и др. Клиническая фармакология. Учебник. Под ред. В.Г.Кукеса, Д.А.Сычева. М.: ГЭОТАР-Медиа, 2015. / Kukes V.G. i dr. Klinicheskaia farmakologiia. Uchebnik. Pod red. V.G.Kukesa, D.A.Sycheva. M.: GEOTAR-Media, 2015. [in Russian]
4. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97 (8A): 52C–60C.
5. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013; 6: 390–9.
6. Силивончик Н.Н. Статины и печень: безопасность. Мед. новости. 2011; 8: 24–30. / Silivonchik N.N. Statiny i pechen': bezopasnost'. Med. novosti. 2011; 8: 24–30. [in Russian]
7. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28 (1): 26–35.
8. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012; 10: 264–71.
9. Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287–92.
10. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62–5.
11. Dongiovanni P, Petta S, Mannisto V et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705–12.
12. Кухарчук В.В. Гиполипидемические препараты. Глава 17 в справочнике по медикаментозному лечению сердечно-сосудистых заболеваний. Под ред. Е.И.Чазова. М.: Практика, 2015; с. 261–2. / Kukharchuk V.V. Gipolipidemicheskie preparaty. Glava 17 v spravochnike po medikamentoznomu lecheniiu serdechno-sosudistykh zabolevanii. Pod red. E.I.Chazova. M.: Praktika, 2015; s. 261–2. [in Russian]
13. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9: 698–705.
14. Lioudaki E, Ganotakis ES, Mikhailidis DP. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011; 17: 3632–43.
15. Korantzopoulos P, Tzimas P, Kalantzi K et al. Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res 2009; 40: 582–9.
16. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009; 205: 533–7.
17. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8 (Suppl. 1): S40–3.
18. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5 (2): 177–93.
19. McKenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19 (8): 689–98.
20. Wlodarczyk J, Sullivan D, Smith M. Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials. Am J Cardiol 2008; 102: 1654–62.
21. Everett BM, Mora S, Glynn RJ et al. Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER). Am J Cardiol 2014; 114: 1682–9.
22. Fellström BC, Jardine AG, Schmieder RE et al for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395–407.
23. Kjekshus J, Apetrei E, Barrios V et al for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–61.
24. Tavazzi L, Tognoni G, Franzosi M et al on behalf of the GISSI-HF investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004; 6: 635–41.
25. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231–9.
26. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223–30.
27. Brewer HB. Benefit-Risk Assessment of Rosuvastatin 10 to 40 Milligrams. Am J Cardiol 2003; 92 (Suppl.): 23K–29K.
28. Bays H, Cohen DE, Chalasani N, Harrison SA. An Assessment by the Statin Liver Safety Task Force: 2014 Update. J Clin Lipidology 2014; 8: S47–S57.
29. Antonopoulos S, Mikros S, Mylonopoulou M et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233–4.
30. Nakahara T, Hyogo H, Kimura Y et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res 2012; 42: 1065–72.
31. Напалков Д.А. Безопасность статинов: что нужно знать практикующему врачу? Рациональная фармакотерапия в кардиологии. 2014; 10 (3): 331–5. / Napalkov D.A. Bezopasnost' statinov: chto nuzhno znat' praktikuiushchemu vrachu? Ratsional'naia farmakoterapiia v kardiologii. 2014; 10 (3): 331–5. [in Russian]
________________________________________________
2. Catapano AL, Graham I, De Backer G et al. Rekomendatsii EOK/EOA po diagnostike i lecheniiu dislipidemii 2016. Rabochaia gruppa Evropeiskogo obshchestva kardiologov (EOK) i Evropeiskogo obshchestva ateroskleroza (EOA) po diagnostike i lecheniiu dislipidemii. Pri uchastii: Evropeiskoi assotsiatsii profilaktiki serdechno-sosudistykh zabolevanii i reabilitatsii (EACPR). Ros. kardiologich. zhurn. 2017; 5 (145): 7–77. [in Russian]
3. Kukes V.G. i dr. Klinicheskaia farmakologiia. Uchebnik. Pod red. V.G.Kukesa, D.A.Sycheva. M.: GEOTAR-Media, 2015. [in Russian]
4. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97 (8A): 52C–60C.
5. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013; 6: 390–9.
6. Silivonchik N.N. Statiny i pechen': bezopasnost'. Med. novosti. 2011; 8: 24–30. [in Russian]
7. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28 (1): 26–35.
8. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012; 10: 264–71.
9. Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287–92.
10. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62–5.
11. Dongiovanni P, Petta S, Mannisto V et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705–12.
12. Kukharchuk V.V. Gipolipidemicheskie preparaty. Glava 17 v spravochnike po medikamentoznomu lecheniiu serdechno-sosudistykh zabolevanii. Pod red. E.I.Chazova. M.: Praktika, 2015; s. 261–2. [in Russian]
13. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9: 698–705.
14. Lioudaki E, Ganotakis ES, Mikhailidis DP. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011; 17: 3632–43.
15. Korantzopoulos P, Tzimas P, Kalantzi K et al. Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res 2009; 40: 582–9.
16. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009; 205: 533–7.
17. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8 (Suppl. 1): S40–3.
18. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5 (2): 177–93.
19. McKenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19 (8): 689–98.
20. Wlodarczyk J, Sullivan D, Smith M. Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials. Am J Cardiol 2008; 102: 1654–62.
21. Everett BM, Mora S, Glynn RJ et al. Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER). Am J Cardiol 2014; 114: 1682–9.
22. Fellström BC, Jardine AG, Schmieder RE et al for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395–407.
23. Kjekshus J, Apetrei E, Barrios V et al for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–61.
24. Tavazzi L, Tognoni G, Franzosi M et al on behalf of the GISSI-HF investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004; 6: 635–41.
25. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231–9.
26. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223–30.
27. Brewer HB. Benefit-Risk Assessment of Rosuvastatin 10 to 40 Milligrams. Am J Cardiol 2003; 92 (Suppl.): 23K–29K.
28. Bays H, Cohen DE, Chalasani N, Harrison SA. An Assessment by the Statin Liver Safety Task Force: 2014 Update. J Clin Lipidology 2014; 8: S47–S57.
29. Antonopoulos S, Mikros S, Mylonopoulou M et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233–4.
30. Nakahara T, Hyogo H, Kimura Y et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res 2012; 42: 1065–72.
31. Napalkov D.A. Bezopasnost' statinov: chto nuzhno znat' praktikuiushchemu vrachu? Ratsional'naia farmakoterapiia v kardiologii. 2014; 10 (3): 331–5. [in Russian]
Авторы
О.Д.Остроумова
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
ostroumova.olga@mail.ru
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2.
ostroumova.olga@mail.ru
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
ostroumova.olga@mail.ru
________________________________________________
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2.
ostroumova.olga@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.